Hints and tips:
...Bristol Myers Squibb; and a Novartis drug to treat heart failure called Entresto....
...A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers Squibb and AbbVie to publish a report on the process they follow when applying...
...Bristol-Myers Squibb has agreed to acquire Turning Point Therapeutics for $4.1bn in the latest in a series of bolt-on acquisitions by pharmaceutical companies looking to bolster their drug pipelines....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Pfizer last month paid $2.3bn to acquire Trillium Therapeutics, which is developing a therapy that it hopes will be transformative for treating blood cancers....
...J&J shares trade on a multiple of 18 times forward earnings, well above Pfizer’s 12 times and Bristol-Myers Squibb’s 9 times. Duato will have to deliver on the vaccine front to justify this premium....
...Pfizer, AbbVie and Bristol-Myers Squibb all have blockbuster drugs due to lose exclusivity soon and have recently sealed multibillion-dollar deals....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...“Together with Pfizer, we are also working with various organisations to support the supply of vaccines to populations worldwide....
...It increased its stakes in AbbVie, Bristol-Myers Squibb and Merck, but sold out of Pfizer....
...Berkshire’s new stake accounted for 1.3 per cent of Bristol-Myers shares outstanding, 1.2 per cent of AbbVie, 0.9 per cent of Merck and less than 0.1 per cent of Pfizer....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Other deals included Bristol-Myers-Squibb’s $74bn takeover of biotech group Celgene and Pfizer’s $11.4bn acquisition of Array BioPharma....
...Pfizer said it was also investing to expand its capacity....
...Early last year Bristol-Myers Squibb purchased Celgene for $93bn, while Pfizer snapped up Array BioPharma for $11bn in June....
...more than $700bn worth of transactions have been agreed in the pharmaceutical and healthcare sector, according to Refinitiv, including AbbVie’s decision to buy the maker of Botox, Allergan, for $63bn; Pfizer...
...Pfizer’s transaction with Mylan is the latest in a wave of large pharma and healthcare deals this year, including Bristol-Myers Squibb’s $90bn acquisition of biotech Celgene, Roche’s $4.8bn takeover of gene...
...There have been a number of blockbuster takeovers this year, including Bristol-Myers Squibb’s purchase of biotech company Celgene for $90bn....
...It recently signed a deal with an alliance between pharmaceutical companies Bristol-Myers Squibb and Pfizer, working towards approval of a sensor and algorithm that could spot atrial fibrillation, a sign...
...Bristol-Myers Squibb’s $90bn takeover of Celgene, struck in the first few days of January, helped unleash a wave of pharma deals this year....
...Albert Bourla, the new chief executive of Pfizer, said the company would “not keep a single dollar” from the rebate reforms, while Pascal Soriot, chief executive of AstraZeneca, said removing the rebates...
...The six chief executives from Merck, Pfizer, AstraZeneca, AbbVie, Sanofi, and Bristol-Myers Squibb, plus an executive president from Johnson & Johnson, will face tough questions on Tuesday on what is fast...
...This would replace the combination of Opdivo and Yervoy, owned by Bristol-Myers Squibb....
...In combination with Pfizer’s drug Inlyta, the medicine showed “clinically meaningful improvements in overall survival” in patients suffering from renal cell carcinoma, the most common form of kidney cancer...
International Edition